t (4; 14)(p16. 3; q32) is strongly associated with a shorter survival in myeloma patients.
JM Winkler, PR Greipp… - British journal of …, 2003 - search.ebscohost.com
JM Winkler, PR Greipp, R Fonseca
British journal of haematology, 2003•search.ebscohost.comComments on the paper'FGFR dysregulation in multiple myeloma,'by T. Rasmussen and
colleagues, published in a 2002 issue of the'British Journal of Haematology,'which showed
no correlation between FGFR3 overexpression and clinical outcome in myeloma. Reference
to the authors' own study which demonstrated a significantly shorter survival in patients
having t (4: 14)(p16. 3; q32).
colleagues, published in a 2002 issue of the'British Journal of Haematology,'which showed
no correlation between FGFR3 overexpression and clinical outcome in myeloma. Reference
to the authors' own study which demonstrated a significantly shorter survival in patients
having t (4: 14)(p16. 3; q32).
Abstract
Comments on the paper'FGFR dysregulation in multiple myeloma,'by T. Rasmussen and colleagues, published in a 2002 issue of the'British Journal of Haematology,'which showed no correlation between FGFR3 overexpression and clinical outcome in myeloma. Reference to the authors' own study which demonstrated a significantly shorter survival in patients having t (4: 14)(p16. 3; q32).
search.ebscohost.com